Geron Q1 2023 Earnings Report $3.93 +0.12 (+3.15%) (As of 12/17/2024 ET) Earnings HistoryForecast Geron EPS ResultsActual EPS-$0.07Consensus EPS -$0.09Beat/MissBeat by +$0.02One Year Ago EPS-$0.09Geron Revenue ResultsActual Revenue$0.02 millionExpected Revenue$0.14 millionBeat/MissMissed by -$120.00 thousandYoY Revenue GrowthN/AGeron Announcement DetailsQuarterQ1 2023Date5/11/2023TimeBefore Market OpensConference Call ResourcesConference CallConference Call TranscriptSlide DeckPress ReleaseGERN Earnings HistoryConference Call AudioYour browser does not support the audio element. Listen Now.Slide DeckFull Screen Slide DeckPowered by We recommended Palantir in 2021, now we’re recommending this... (Ad)My research indicates there is only one investment that can meet AI's unprecedented demand for energy.Click to get the name and ticker symbol Geron Earnings HeadlinesGeron's (GERN) "Buy" Rating Reiterated at Needham & Company LLCDecember 15 at 3:33 AM | americanbankingnews.comBuy Rating on Geron Driven by EU Approval Prospects and Strategic Commercialization of RyteloDecember 14 at 7:14 AM | markets.businessinsider.comMedia Humiliated: Demo of Elon’s Tech Proves They’re WrongElon Musk believes his new AI product will be worth an incredible $9 trillion. But the mainstream media is not buying it.December 17, 2024 | Brownstone Research (Ad)Geron Gets Positive CHMP Opinion For RYTELO In Transfusion-Dependent Anemia Due To Lower-Risk MDSDecember 13, 2024 | markets.businessinsider.comGeron announces positive CHMP opinion for RyteloDecember 13, 2024 | tipranks.comGeron Corp (GERN) Receives Positive CHMP Opinion for RYTELO in Treating Blood CancerDecember 13, 2024 | gurufocus.comSee More Geron Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like Geron? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Geron and other key companies, straight to your email. Email Address About GeronGeron (NASDAQ:GERN), a late-stage clinical biopharmaceutical company, focuses on the development and commercialization of therapeutics for myeloid hematologic malignancies. It develops imetelstat, a telomerase inhibitor that is in Phase 3 clinical trials, which inhibits the uncontrolled proliferation of malignant stem and progenitor cells in myeloid hematologic malignancies for the treatment of low or intermediate-1 risk myelodysplastic syndromes and intermediate-2 or high-risk myelofibrosis. The company was incorporated in 1990 and is headquartered in Foster City, California.View Geron ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Earnings By Country U.S. Earnings Reports Canadian Earnings Reports U.K. Earnings Reports Latest Articles History Hints at a Rebound for Toll Brothers After EarningsAlibaba Stock: Why Earnings Make It a Buy Despite the Recent DipMercadoLibre Down 23% After Missed Earnings: Time to Buy the Dip?Roblox Stock Soars 22% After Q3 Earnings – A Turning Point Ahead?Apple Earnings - When Really Good Just Isn’t Good Enough Roblox Stock Set for More Gains After Strong Earnings ReportAmazon: Why Analysts Think It's a Solid Buy Ahead of Earnings Upcoming Earnings Cintas (12/19/2024) Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
